GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
A Study Comparing The Safety, Tolerability and Efficacy of Trizivir VS Combivir & Atazanavir In Subjects With HIV
- Conditions
- Infection, Human Immunodeficiency Virus IHIV Infection
- First Posted Date
- 2004-05-10
- Last Posted Date
- 2017-05-24
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT00082394
- Locations
- 🇲🇽
GSK Investigational Site, Monterrey, Nuevo León, Mexico
506U78 in Treating Patients With Chronic Lymphocytic Leukemia That Has Not Responded to Fludarabine or Alkylating Agents
- Conditions
- Leukemia
- First Posted Date
- 2004-03-31
- Last Posted Date
- 2013-07-18
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT00003635
- Locations
- 🇺🇸
Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸Johns Hopkins Oncology Center, Baltimore, Maryland, United States
🇺🇸Clinical Studies, Ltd., Denver, Colorado, United States
Vinorelbine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
- Conditions
- Lung Cancer
- First Posted Date
- 2004-03-24
- Last Posted Date
- 2014-01-06
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT00005865
- Locations
- 🇺🇸
NorthBay Healthcare System, Fairfield, California, United States
🇺🇸University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸Ireland Cancer Center, Cleveland, Ohio, United States
A Clinical Research Study For The Suppression And Treatment Of Genital Herpes Infection In HIV-Infected Persons
- First Posted Date
- 2004-03-19
- Last Posted Date
- 2020-11-24
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 7
- Registration Number
- NCT00079911
- Locations
- 🇭🇰
GSK Investigational Site, Kowloon Bay, Hong Kong
Capecitabine (XELODA) With Or Without Lapatinib (GW572016) For Women With Refractory Advanced or Metastatic Breast Cancer
- First Posted Date
- 2004-03-03
- Last Posted Date
- 2010-12-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 408
- Registration Number
- NCT00078572
Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer
- First Posted Date
- 2004-01-09
- Last Posted Date
- 2015-05-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 580
- Registration Number
- NCT00075270
- Locations
- 🇹🇷
GSK Investigational Site, Istanbul, Turkey
A Study Of Oral GW572016 In Advanced Or Metastatic Non-Small Cell Lung Cancer
- Conditions
- Lung Cancer, Non-Small Cell
- Interventions
- Drug: GW572016 (lapatinib)
- First Posted Date
- 2003-11-17
- Last Posted Date
- 2017-02-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 131
- Registration Number
- NCT00073008
- Locations
- 🇨🇦
GSK Investigational Site, Levis, Quebec, Canada
Clinical Study Of Schizophrenia in Both Men and Women
- Conditions
- Schizophrenia
- First Posted Date
- 2003-10-31
- Last Posted Date
- 2016-09-01
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 176
- Registration Number
- NCT00071747
- Locations
- 🇺🇸
GSK Investigational Site, Milwaukee, Wisconsin, United States
OASIS-6 : The Safety and Efficacy of Fondaparinux Versus Control Therapy in Patients With ST Segment Elevation Acute Myocardial Infarction
- Conditions
- Thromboembolism
- Interventions
- Drug: fondaparinux - UFH not indicatedOther: Control - UFH not indicatedDrug: Fondaparinux - UFH indicatedDrug: Control - UFH
- First Posted Date
- 2003-10-17
- Last Posted Date
- 2016-09-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 12092
- Registration Number
- NCT00064428
Study Of AVANDAMET® With Or Without Insulin In Type II Diabetes Mellitus Patients. AVANDAMET® is a Registered Trademark of the GSK Group of Companies.
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: Rosiglitazone/metformin
- First Posted Date
- 2003-10-03
- Last Posted Date
- 2016-09-01
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 272
- Registration Number
- NCT00069836
- Locations
- 🇪🇸
GSK Investigational Site, Vigo/Pontevedra, Spain